DIPYRIDAMOLE

Post-LOE

dipyridamole

Hikma

ANDAINJECTIONINJECTABLE

Approved

Oct 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DIPYRIDAMOLE (dipyridamole) by Hikma. Approved for platelet aggregation inhibitor [epc]. First approved in 1996.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

Pharmacologic Class:

Platelet Aggregation Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (14)

NCT05166876Phase 2Terminated

Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19

Started Feb 2022

26 enrolled

COVID-19

NCT02121756Phase 1/2Completed

Dipyridamole for Immune Activation in HIV

Started Jul 2014

40 enrolled

HIV Infection

NCT00808314Phase 4Unknown

Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress

Started Dec 2008

32 enrolled

Coronary Artery Disease

NCT02262793Phase 1Completed

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Started May 2004

24 enrolled

Healthy

NCT00129038Phase 4Completed

Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients

Started Apr 2004

11 enrolled

Coronary Arteriosclerosis

Worked on DIPYRIDAMOLE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.